These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Transforming growth factor-beta and its receptors in scleroderma]. QIAN H; ZHENG M Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 38(4):415-21. PubMed ID: 19693982 [TBL] [Abstract][Full Text] [Related]
6. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma. Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317 [TBL] [Abstract][Full Text] [Related]
7. Effect of prolyl 4-hydroxylase inhibitor on fibroblast collagen production in vitro: an approach to the treatment of systemic sclerosis. Kawaguchi Y; Harigai M; Kitani A; Suzuki K; Kawakami M; Ishizuka T; Hidaka T; Hara M; Kawagoe M; Nakamura H J Rheumatol; 1992 Nov; 19(11):1710-5. PubMed ID: 1337110 [TBL] [Abstract][Full Text] [Related]
8. Scleroderma and related conditions. Mitchell H; Bolster MB; LeRoy EC Med Clin North Am; 1997 Jan; 81(1):129-49. PubMed ID: 9012758 [TBL] [Abstract][Full Text] [Related]
9. Lung involvement in systemic sclerosis sine scleroderma treated by plasma exchange. Ferri C; Bernini L; Gremignai G; Latorraca A; Fazzi P; Tavon A; Solfanelli S; Bombardieri S Int J Artif Organs; 1992 Jul; 15(7):426-31. PubMed ID: 1516994 [TBL] [Abstract][Full Text] [Related]
11. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968 [TBL] [Abstract][Full Text] [Related]
12. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. Nakashima T; Jinnin M; Yamane K; Honda N; Kajihara I; Makino T; Masuguchi S; Fukushima S; Okamoto Y; Hasegawa M; Fujimoto M; Ihn H J Immunol; 2012 Apr; 188(8):3573-83. PubMed ID: 22403442 [TBL] [Abstract][Full Text] [Related]
13. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis. Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032 [TBL] [Abstract][Full Text] [Related]
14. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Kuhn C; McDonald JA Am J Pathol; 1991 May; 138(5):1257-65. PubMed ID: 2024710 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Brinckmann J; Kim S; Wu J; Reinhardt DP; Batmunkh C; Metzen E; Notbohm H; Bank RA; Krieg T; Hunzelmann N Matrix Biol; 2005 Oct; 24(7):459-68. PubMed ID: 16139999 [TBL] [Abstract][Full Text] [Related]
16. Biomedical research. More than skin deep. Cahoon L Science; 2008 Oct; 322(5902):667-9. PubMed ID: 18974325 [No Abstract] [Full Text] [Related]
17. Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. Xu WD; Leroy EC; Smith EA J Rheumatol; 1991 Feb; 18(2):241-6. PubMed ID: 2023218 [TBL] [Abstract][Full Text] [Related]